Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lulizumab or BMS-986142 versus placebo in primary Sjögren's syndrome
2016-000101-37Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Modality
- Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing lulizumab, BMS-986142 and placebo (3 arms). Primary endpoint: Change from baseline in ESSDAI score at Week 12. Started Mar 2017; status: completed.
02
Drugs
lulizumab pegolBMS-986142
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2016-000101-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000101-37.